Primary ovarian insufficiency (POI)

What changes during this transition

Primary ovarian insufficiency affects roughly 1% of women under 40 and about 0.1% under 30. The diagnostic picture is amenorrhea or irregular menses, FSH greater than 25-40 IU/L on two occasions separated by four weeks, low estradiol, and typically undetectable or very low AMH. The etiologies divide into genetic (Turner syndrome including mosaic 45,X, FMR1 premutation with 55-200 CGG repeats, BRCA1/2, autosomal genes — collectively roughly 10-15% of cases), autoimmune (APS-1 with AIRE mutations, APS-2, isolated ovarian antibodies, often clustering with thyroid and adrenal autoimmunity — roughly 5-30%), iatrogenic (alkylating chemotherapy in particular, pelvic radiation, surgical), and idiopathic, which remains the majority. Terminology shifted from 'premature ovarian failure' to 'primary ovarian insufficiency' to reflect that ovarian function is intermittent rather than uniformly absent — roughly 5-10% of women with POI conceive spontaneously, which has clinical implications for both contraception counseling and how the diagnosis is communicated. The symptom picture mirrors menopausal symptoms — hot flashes, night sweats, vaginal dryness, dyspareunia, fatigue, mood changes, low libido — overlaid with the diagnostic weight of infertility at a life stage when most women have not yet completed family-building. The long-term sequelae are the load-bearing piece of why POI gets treated aggressively: untreated POI carries elevated risks of osteoporosis, cardiovascular disease, cognitive decline, depression, and premature mortality, driven by the decades of estrogen deficiency that would not be present in age-typical menopause. Standard of care has a non-negotiable core: hormone replacement therapy until the age of natural menopause, conventionally around 51. The dosing is higher than menopausal HRT — POI patients need physiologic replacement of what their ovaries would have produced, not the supplementation dosing used for symptom management in a 55-year-old. Transdermal estradiol is generally preferred for cardiovascular and venous thromboembolism risk profile; progestin is added if the uterus is intact for endometrial protection. Combined oral contraceptives are an alternative HRT vehicle and offer the contraception benefit (relevant given the 5-10% spontaneous conception rate), but they are less physiologic. Beyond HRT, monitoring includes baseline and serial DEXA every 1-2 years for bone density, calcium and vitamin D optimization, cardiovascular risk screening (lipids, blood pressure), and mental health attention — depression is meaningfully elevated in POI populations. Fertility management is the piece where the peptide community most often inserts itself. The established pathway for women with POI who want biological children involves oocyte donation IVF, which has high success rates and is the realistic primary option for most patients. Ovarian tissue cryopreservation before known iatrogenic exposure (chemotherapy, radiation) is established for the narrow population where the exposure is anticipated and can be planned around. The experimental approaches — ovarian platelet-rich plasma (PRP) injection, in-vitro activation (IVA) per the Kawamura group's PI3K-PTEN pathway work, stem cell ovarian transplant, ovarian growth factor injections — have published case series but no high-quality randomized evidence; they should be understood as research, not standard care. Counseling and peer support are clinically meaningful — the Daisy Network in the UK, the International Premature Ovarian Insufficiency Association, and other POI-specific patient communities exist because the condition has psychological weight that pure medical management doesn't fully address. Peptides do not appear in any major POI guideline. BPC-157 and TB-500 are positioned as ovarian healing or regeneration, but POI is follicular pool exhaustion, not tissue injury — there is no wound bed to repair or follicle to regenerate de novo, and neither peptide has any published ovarian evidence. NMN is positioned via mitochondrial reproductive-aging framing that does not extend to POI, where the etiologies are genetic, autoimmune, iatrogenic, or idiopathic rather than primarily mitochondrial. Thymosin alpha-1 and LL-37 raise specific concern in the autoimmune POI subtype (5-30% of cases) and the broader APS clusters, because both are immune-activating in ways that could plausibly amplify autoimmune destruction at the ovary, adrenal, or thyroid — and neither has any published rationale in the non-autoimmune etiologies either.